Insider transactions

EDGAR

AN2 Therapeutics, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
1 transactions, 2,098 shares
Sum of shares × price per share: 11,601.94
Open-market sales (code S)
21 transactions, 111,638 shares
Sum of shares × price per share: 406,138.0967

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 120

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-05 Filed 2026-11-06Eizen Joshua M Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,8264.22
11,925.72

Derived: shares × price per share. Exact value 11925.72.

207,546Direct (D) No
F1, F2, F3
  • F1 Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on November 4, 2026.
  • F2 Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (c) 58,500 RSUs which vest as follows 1/4th of the RSUs vest annually over four years from January 1, 2025 and (d) 50,000 RSUs which vest as follows: 1/4th of RSUs vest annually over four years from January 1, 2026, in each case subject to the Reporting Person's continuous service as of such date.
  • F3 Reflects the adjusted total which includes the purchase of 3,818 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2026.
Open filing 0001193125-26-452184 Read from the filing’s XML Dispute this row
2026-10-12 Filed 2026-10-13Aziz Kabeer Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,4650—61,571Direct (D) No
F1
  • F1 Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
Open filing 0001193125-26-420639 Read from the filing’s XML Dispute this row
2026-10-12 Filed 2026-10-13Marks Gilbert Lynn Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,2830—84,156Direct (D) No
F1
  • F1 Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
Open filing 0001193125-26-420643 Read from the filing’s XML Dispute this row
2026-10-12 Filed 2026-10-13Martin Patricia A. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)3890—19,252Direct (D) No
F1
  • F1 Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
Open filing 0001193125-26-420641 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-16Trenor Cameron C. III Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)116,6670—116,667Direct (D) No
F1
  • F1 Represents restricted stock units (RSUs) which vest as follows: 10,400 RSUs vest on January 1, 2027, prorated from August 24, 2026, the vesting start date, and the remaining RSUs vest in equal annual installments on each January 1, 2028, January 1, 2029 and January 1, 2030, subject to the Reporting Person's continuous service through each applicable vesting date.
Open filing 0001193125-26-393274 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-16Trenor Cameron C. III Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to by) — underlying Common Stock (233,333) — exercise price 5.36
Acquired (A)233,3330—233,333Direct (D) No
F2
  • F2 The shares subject to the stock option vest as follows: 25% of the shares vest on August 24, 2027 and the remaining shares vest in equal monthly installments over the subsequent 36 months, subject to the Reporting Person's continuous service through each applicable vesting date.
Open filing 0001193125-26-393274 Read from the filing’s XML Dispute this row
2026-09-09 Filed 2026-09-11Readnour Robin Shane Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)5236.0243
3,150.7089

Derived: shares × price per share. Exact value 3150.7089.

557,467Indirect (I) See footnotesYes
F1, F3, F4, F5
  • F1 The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP (MGC 2018 LP) on April 23, 2026.
  • F3 Represents the weighted average sale price for multiple transactions ranging from $6.02 to $6.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.
  • F4 MGC Venture Partners 2018 GP, LLC (MGC 2018 GP) is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
  • F5 Shares held directly by MGC 2018 LP.
Open filing 0001193125-26-389545 Read from the filing’s XML Dispute this row
2026-09-09 Filed 2026-09-11Readnour Robin Shane Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)5856.0243
3,524.2155

Derived: shares × price per share. Exact value 3524.2155.

624,765Indirect (I) See footnotesYes
F2, F3, F4, F6
  • F2 The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP (MGC 2018 QP) on April 23, 2026.
  • F3 Represents the weighted average sale price for multiple transactions ranging from $6.02 to $6.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.
  • F4 MGC Venture Partners 2018 GP, LLC (MGC 2018 GP) is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
  • F6 Shares held directly by MGC 2018 QP.
Open filing 0001193125-26-389545 Read from the filing’s XML Dispute this row
2026-09-08 Filed 2026-09-08Readnour Robin Shane Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4,7256.0183
28,436.4675

Derived: shares × price per share. Exact value 28436.4675.

557,990Indirect (I) See footnotesYes
F1, F3, F4, F5
  • F1 The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP (MGC 2018 LP) on April 23, 2026.
  • F3 Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.
  • F4 MGC Venture Partners 2018 GP, LLC (MGC 2018 GP) is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
  • F5 Shares held directly by MGC 2018 LP.
Open filing 0001193125-26-385511 Read from the filing’s XML Dispute this row
2026-09-08 Filed 2026-09-08Readnour Robin Shane Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)5,2946.0183
31,860.8802

Derived: shares × price per share. Exact value 31860.8802.

625,350Indirect (I) See footnotesYes
F2, F3, F4, F6
  • F2 The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP (MGC 2018 QP) on April 23, 2026.
  • F3 Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.
  • F4 MGC Venture Partners 2018 GP, LLC (MGC 2018 GP) is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
  • F6 Shares held directly by MGC 2018 QP.
Open filing 0001193125-26-385511 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-08Readnour Robin Shane Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,8776.0698
17,462.8146

Derived: shares × price per share. Exact value 17462.8146.

562,715Indirect (I) See footnotesYes
F1, F3, F4, F5
  • F1 The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP (MGC 2018 LP) on April 23, 2026.
  • F3 Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.
  • F4 MGC Venture Partners 2018 GP, LLC (MGC 2018 GP) is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
  • F5 Shares held directly by MGC 2018 LP.
Open filing 0001193125-26-385511 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-08Readnour Robin Shane Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,2236.0698
19,562.9654

Derived: shares × price per share. Exact value 19562.9654.

630,644Indirect (I) See footnotesYes
F2, F3, F4, F6
  • F2 The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP (MGC 2018 QP) on April 23, 2026.
  • F3 Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.
  • F4 MGC Venture Partners 2018 GP, LLC (MGC 2018 GP) is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
  • F6 Shares held directly by MGC 2018 QP.
Open filing 0001193125-26-385511 Read from the filing’s XML Dispute this row
2026-09-01 Filed 2026-09-04Williams Sarah Joanne Officer: Principal Accounting Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2725.53
1,504.16

Derived: shares × price per share. Exact value 1504.16.

66,311Direct (D) No
F1, F2
  • F1 Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on August 28, 2026.
  • F2 Includes (a) 48,375 RSUs which vest as follows: 1/4th of the shares vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2026, and the balance of (b) 10,938 RSUs which vest as follows: 1/4th of the RSUs vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (c) 11,850 RSUs which vest as follows: 1/16th of the RSUs vests in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. A total of 4,038 shares from the aggregate number of the RSUs issued under (b) and (c) above were sold to cover taxes and a total of 814 shares were sold on the open market.
Open filing 0001193125-26-383697 Read from the filing’s XML Dispute this row
2026-09-01 Filed 2026-09-02FitzPatrick Margaret M Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)2,0985.53
11,601.94

Derived: shares × price per share. Exact value 11601.94.

10,708Direct (D) No— Open filing 0001193125-26-380595 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-19Readnour Robin Shane Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)16,6966.0082
100,312.9072

Derived: shares × price per share. Exact value 100312.9072.

565,592Indirect (I) See footnotesYes
F1, F3, F4, F5
  • F1 The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP (MGC 2018 LP) on April 23, 2026.
  • F3 Represents the weighted average sale price for multiple transactions ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.
  • F4 MGC Venture Partners 2018 GP, LLC (MGC 2018 GP) is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
  • F5 Shares held directly by MGC 2018 LP.
Open filing 0001193125-26-357225 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-19Readnour Robin Shane Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)18,7066.0082
112,389.3892

Derived: shares × price per share. Exact value 112389.3892.

633,867Indirect (I) See footnotesYes
F2, F3, F4, F6
  • F2 The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP (MGC 2018 QP) on April 23, 2026.
  • F3 Represents the weighted average sale price for multiple transactions ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.
  • F4 MGC Venture Partners 2018 GP, LLC (MGC 2018 GP) is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
  • F6 Shares held directly by MGC 2018 QP.
Open filing 0001193125-26-357225 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-14Zakrzewski Joseph S Director
G

Bona fide gift

Common Stock
Disposed (D)405,8800—0Indirect (I) See footnoteNo
F1, F2
  • F1 Reflects a gift of shares to the children of the Reporting Person.
  • F2 The shares are held by Nancy Zakrzewski TTEE Z3 Trust U/A DTD 11/25/14 (Z3 Trust). The Reporting Person disavows beneficial ownership of the shares held by Z3 Trust.
Open filing 0001193125-26-351801 Read from the filing’s XML Dispute this row
2026-07-10 Filed 2026-07-10Aziz Kabeer Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,8520—59,106Direct (D) No
F1
  • F1 Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
Open filing 0001193125-26-301167 Read from the filing’s XML Dispute this row
2026-07-10 Filed 2026-07-10Marks Gilbert Lynn Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,7890—81,873Direct (D) No
F1
  • F1 Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
Open filing 0001193125-26-301166 Read from the filing’s XML Dispute this row
2026-07-10 Filed 2026-07-10Martin Patricia A. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)7660—18,863Direct (D) No
F1
  • F1 Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
Open filing 0001193125-26-301165 Read from the filing’s XML Dispute this row
2026-07-08 Filed 2026-07-10Eizen Joshua M Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)5,9454.172
24,802.54

Derived: shares × price per share. Exact value 24802.540.

206,554Direct (D) No
F1, F2, F3
  • F1 Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on July 1, 2026.
  • F2 Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (c) 58,500 RSUs which vest as follows 1/4th of the RSUs vest annually over four years from January 1, 2025 and (d) 50,000 RSUs which vest as follows: 1/4th of RSUs vest annually over four years from January 1, 2026, in each case subject to the Reporting Person's continuous service as of such date.
  • F3 Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2026.
Open filing 0001193125-26-301092 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02Williams Sarah Joanne Officer: Principal Accounting Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2654.43
1,173.95

Derived: shares × price per share. Exact value 1173.95.

66,583Direct (D) No
F1, F2
  • F1 Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on May 29, 2026.
  • F2 Includes (a) 48,375 RSUs which vest as follows: 1/4th of the shares vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2026, and the balance of (b) 10,938 RSUs which vest as follows: 1/4th of the RSUs vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (c) 11,850 RSUs which vest as follows: 1/16th of the RSUs vests in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. A total of 3,766 shares from the aggregate number of the RSUs issued under (b) and (c) above were sold to cover taxes and a total of 814 shares were sold on the open market.
Open filing 0001193125-26-253622 Read from the filing’s XML Dispute this row
2026-04-10 Filed 2026-04-10Aziz Kabeer Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)3,7750—56,254Direct (D) No
F1
  • F1 Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
Open filing 0001193125-26-151632 Read from the filing’s XML Dispute this row
2026-04-10 Filed 2026-04-10Marks Gilbert Lynn Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)3,7750—79,084Direct (D) No
F1
  • F1 Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
Open filing 0001193125-26-151628 Read from the filing’s XML Dispute this row
2026-04-10 Filed 2026-04-10Martin Patricia A. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,1920—18,097Direct (D) No
F1
  • F1 Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
Open filing 0001193125-26-151626 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Easom Eric Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (249,999) — exercise price 3.91
Acquired (A)249,999——249,999Direct (D) No
F1, F3, F2
  • F1 The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the Premium End Date (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The Premium End Date means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The option is fully vested.
Open filing 0001193125-26-120192 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Easom Eric Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (249,999) — exercise price 6.596
Disposed (D)249,999——0Direct (D) No
F3, F2
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The option is fully vested.
Open filing 0001193125-26-120192 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Easom Eric Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (225,000) — exercise price 3.91
Acquired (A)225,000——225,000Direct (D) No
F1, F3, F4
  • F1 The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the Premium End Date (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The Premium End Date means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F4 The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date.
Open filing 0001193125-26-120192 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Easom Eric Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (225,000) — exercise price 17.28
Disposed (D)225,000——0Direct (D) No
F3, F4
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F4 The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date.
Open filing 0001193125-26-120192 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Easom Eric Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (267,650) — exercise price 3.91
Acquired (A)267,650——267,650Direct (D) No
F1, F3, F5
  • F1 The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the Premium End Date (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The Premium End Date means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F5 The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.
Open filing 0001193125-26-120192 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Easom Eric Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (267,650) — exercise price 11.99
Disposed (D)267,650——0Direct (D) No
F3, F5
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F5 The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.
Open filing 0001193125-26-120192 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Eizen Joshua M Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (92,000) — exercise price 3.91
Acquired (A)92,000——92,000Direct (D) No
F1, F3, F2
  • F1 The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the Premium End Date (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The Premium End Date means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The shares subject to the option vest as follows: 25% of the shares shall vest on the anniversary of September 29, 2022, and the remainder of the shares shall vest ratably monthly over the subsequent 36 months, subject to the Reporting Person's continuous service through each applicable vesting date.
Open filing 0001193125-26-120210 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Eizen Joshua M Officer: See Remarks
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (92,000) — exercise price 17.88
Disposed (D)92,000——0Direct (D) No
F3, F2
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The shares subject to the option vest as follows: 25% of the shares shall vest on the anniversary of September 29, 2022, and the remainder of the shares shall vest ratably monthly over the subsequent 36 months, subject to the Reporting Person's continuous service through each applicable vesting date.
Open filing 0001193125-26-120210 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Eizen Joshua M Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (50,150) — exercise price 3.91
Acquired (A)50,150——50,150Direct (D) No
F1, F3, F4
  • F1 The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the Premium End Date (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The Premium End Date means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F4 The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.
Open filing 0001193125-26-120210 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Eizen Joshua M Officer: See Remarks
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (50,150) — exercise price 14.29
Disposed (D)50,150——0Direct (D) No
F3, F4
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F4 The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.
Open filing 0001193125-26-120210 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Martin Patricia A. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (24,999) — exercise price 3.91
Acquired (A)24,999——24,999Direct (D) No
F1, F3, F2
  • F1 The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the Premium End Date (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The Premium End Date means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The option is fully vested.
Open filing 0001193125-26-120223 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Martin Patricia A. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (24,999) — exercise price 6.596
Disposed (D)24,999——0Direct (D) No
F3, F2
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The option is fully vested.
Open filing 0001193125-26-120223 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Martin Patricia A. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (10,362) — exercise price 3.91
Acquired (A)10,362——10,362Direct (D) No
F1, F3, F2
  • F1 The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the Premium End Date (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The Premium End Date means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The option is fully vested.
Open filing 0001193125-26-120223 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Martin Patricia A. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (10,362) — exercise price 17.28
Disposed (D)10,362——0Direct (D) No
F3, F2
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The option is fully vested.
Open filing 0001193125-26-120223 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Martin Patricia A. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (23,742) — exercise price 3.91
Acquired (A)23,742——23,742Direct (D) No
F1, F3, F2
  • F1 The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the Premium End Date (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The Premium End Date means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The option is fully vested.
Open filing 0001193125-26-120223 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Martin Patricia A. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (23,742) — exercise price 5.91
Disposed (D)23,742——0Direct (D) No
F3, F2
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The option is fully vested.
Open filing 0001193125-26-120223 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Spigelman Melvin K Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (16,941) — exercise price 3.91
Acquired (A)16,941——16,941Direct (D) No
F1, F3, F2
  • F1 The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the Premium End Date (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The Premium End Date means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The option is fully vested.
Open filing 0001193125-26-120207 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Spigelman Melvin K Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (16,941) — exercise price 9.308
Disposed (D)16,941——0Direct (D) No
F3, F2
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The option is fully vested.
Open filing 0001193125-26-120207 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Spigelman Melvin K Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (10,362) — exercise price 3.91
Acquired (A)10,362——10,362Direct (D) No
F1, F3, F2
  • F1 The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the Premium End Date (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The Premium End Date means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The option is fully vested.
Open filing 0001193125-26-120207 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Spigelman Melvin K Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (10,362) — exercise price 17.28
Disposed (D)10,362——0Direct (D) No
F3, F2
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The option is fully vested.
Open filing 0001193125-26-120207 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Spigelman Melvin K Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (23,742) — exercise price 3.91
Acquired (A)23,742——23,742Direct (D) No
F1, F3, F2
  • F1 The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the Premium End Date (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The Premium End Date means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The option is fully vested.
Open filing 0001193125-26-120207 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Spigelman Melvin K Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (23,742) — exercise price 5.91
Disposed (D)23,742——0Direct (D) No
F3, F2
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The option is fully vested.
Open filing 0001193125-26-120207 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Aziz Kabeer Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (20,724) — exercise price 3.91
Acquired (A)20,724——20,724Direct (D) No
F1, F3, F2
  • F1 The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the Premium End Date (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The Premium End Date means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The option is fully vested.
Open filing 0001193125-26-120226 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Aziz Kabeer Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (20,724) — exercise price 17.28
Disposed (D)20,724——0Direct (D) No
F3, F2
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The option is fully vested.
Open filing 0001193125-26-120226 Read from the filing’s XML Dispute this row
2026-03-19 Filed 2026-03-23Aziz Kabeer Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (23,742) — exercise price 3.91
Acquired (A)23,742——23,742Direct (D) No
F1, F3, F2
  • F1 The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the Premium End Date (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The Premium End Date means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
  • F3 On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
  • F2 The option is fully vested.
Open filing 0001193125-26-120226 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–50 of 88

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Vivo Capital, LLC 3,153,640 SH16,777,365 dollarsUnchanged Prior quarter: 3,153,640Open filing 0001213900-26-119459 Filed 2026-11-13 Dispute this row
Commodore Capital LP 2,933,680 SH15,607,178 dollarsUnchanged Prior quarter: 2,933,680Open filing 0001831942-26-000052 Filed 2026-11-16 Dispute this row
MILLENNIUM MANAGEMENT LLC 2,476,231 SH13,173,549 dollarsHigher by 157,539 Prior quarter: 2,318,692Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager1,771,563 SH9,424,716 dollarsHigher by 106,069 Prior quarter: 1,665,494Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
Spruce Street Capital LP 1,752,011 SH9,320,699 dollarsHigher by 90,938 Prior quarter: 1,661,073Open filing 0002050194-26-000006 Filed 2026-11-13 Dispute this row
ACORN CAPITAL ADVISORS, LLC 1,300,000 SH6,916,000 dollarsNot in the prior quarter’s filings read Open filing 0001636587-26-000102 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 1,238,705 SH6,589,911 dollarsUnchanged Prior quarter: 1,238,705Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
ADAGE CAPITAL PARTNERS GP, L.L.C. 1,000,000 SH5,320,000 dollarsUnchanged Prior quarter: 1,000,000Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager984,080 SH5,235,305 dollarsHigher by 32,083 Prior quarter: 951,997Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
Boxer Capital Management, LLC 944,035 SH5,022,266 dollarsHigher by 195,000 Prior quarter: 749,035Open filing 0001213900-26-120704 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager684,122 SH3,640,746 dollarsLower by 13,684 Prior quarter: 697,806Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager634,655 SH3,376,365 dollarsHigher by 546,722 Prior quarter: 87,933Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
Tetragon Partners GP Ltd 603,424 SH3,210,216 dollarsNot in the prior quarter’s filings read Open filing 0000919574-26-008018 Filed 2026-11-16 Dispute this row
SummitTX Capital, L.P. 597,793 SH3,180,259 dollarsHigher by 340 Prior quarter: 597,453Open filing 0002052310-26-000008 Filed 2026-11-16 Dispute this row
Sio Capital Management, LLC 548,103 SH2,915,908 dollarsHigher by 18,170 Prior quarter: 529,933Open filing 0001214659-26-014302 Filed 2026-11-16 Dispute this row
AMERIPRISE FINANCIAL INC Partly reported under another manager537,225 SH2,858,037 dollarsHigher by 161 Prior quarter: 537,064Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row
Ally Bridge Group (NY) LLC 526,315 SH2,799,996 dollarsUnchanged Prior quarter: 526,315Open filing 0001193125-26-463652 Filed 2026-11-16 Dispute this row
Woodline Partners LP 447,420 SH2,380,274 dollarsLower by 12,385 Prior quarter: 459,805Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager444,468 SH2,364,570 dollarsHigher by 132,866 Prior quarter: 311,602Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
Prosight Management, LP 350,877 SH1,866,666 dollarsLower by 123,761 Prior quarter: 474,638Open filing 0001420506-26-002713 Filed 2026-11-13 Dispute this row
Stonepine Capital Management, LLC 350,877 SH1,866,666 dollarsLower by 200,815 Prior quarter: 551,692Open filing 0001440771-26-000027 Filed 2026-11-13 Dispute this row
Almitas Capital LLC 349,068 SH1,857,042 dollarsLower by 1,120,061 Prior quarter: 1,469,129Open filing 0002073679-26-000181 Filed 2026-11-17 Dispute this row
Balyasny Asset Management L.P. 287,250 SH1,528,170 dollarsLower by 268,777 Prior quarter: 556,027Open filing 0001193125-26-463223 Filed 2026-11-16 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager255,878 SH1,361,271 dollarsHigher by 245,693 Prior quarter: 10,185Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
Seven Fleet Capital Management LP 254,309 SH1,352,924 dollarsHigher by 45,363 Prior quarter: 208,946Open filing 0001013594-26-001198 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager251,686 SH1,338,970 dollarsHigher by 177,600 Prior quarter: 74,086Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Russell Investments Group, Ltd. Partly reported under another manager222,225 SH1,182,238 dollarsHigher by 220,113 Prior quarter: 2,112Open filing 0001193125-26-451241 Filed 2026-11-06 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager209,978 SH1,117,083 dollarsLower by 4,943 Prior quarter: 214,921Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
VANGUARD FIDUCIARY TRUST CO 195,856 SH1,041,954 dollarsLower by 1,064 Prior quarter: 196,920Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 180,924 SH962,516 dollarsHigher by 1,330 Prior quarter: 179,594Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
ACUTA CAPITAL PARTNERS, LLC 142,051 SH755,711 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-127905 Filed 2026-11-16 Dispute this row
MARSHALL WACE, LLP Partly reported under another manager106,143 SH564,681 dollarsNot in the prior quarter’s filings read Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row
MORGAN STANLEY Partly reported under another manager81,631 SH434,277 dollarsHigher by 32,252 Prior quarter: 49,379Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager80,100 SH426,132 dollarsLower by 49,600 Prior quarter: 129,700Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
TORONTO DOMINION BANK 78,025 SH415,093 dollarsNot in the prior quarter’s filings read Open filing 0002052595-26-000123 Filed 2026-11-16 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager76,045 SH404,560 dollarsUnchanged Prior quarter: 76,045Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager67,865 SH361,042 dollarsHigher by 189 Prior quarter: 67,676Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 64,220 SH341,650 dollarsUnchanged Prior quarter: 64,220Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
BRIDGEWAY CAPITAL MANAGEMENT, LLC 60,909 SH324,036 dollarsHigher by 1,009 Prior quarter: 59,900Open filing 0001107261-26-000007 Filed 2026-11-16 Dispute this row
ADAR1 Capital Management, LLC 58,808 SH312,859 dollarsUnchanged Prior quarter: 58,808Open filing 0001940272-26-000033 Filed 2026-11-16 Dispute this row
Empowered Funds, LLC Partly reported under another manager58,009 SH308,608 dollarsNot in the prior quarter’s filings read Open filing 0001592828-26-000008 Filed 2026-11-13 Dispute this row
AMERICAN CENTURY COMPANIES INC Partly reported under another manager51,392 SH273,406 dollarsNot in the prior quarter’s filings read Open filing 0000748054-26-000009 Filed 2026-11-20 Dispute this row
CAPTRUST FINANCIAL ADVISORS 41,297 SH219,700 dollarsHigher by 1,132 Prior quarter: 40,165Open filing 0001062993-26-005930 Filed 2026-11-12 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager40,317 SH214,486 dollarsLower by 105,486 Prior quarter: 145,803Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
Velan Capital Investment Management LP 40,000 SH212,800 dollarsUnchanged Prior quarter: 40,000Open filing 0001848809-26-000006 Filed 2026-11-16 Dispute this row
Walleye Capital LLC 39,972 SH212,651 dollarsLower by 32,167 Prior quarter: 72,139Open filing 0001758720-26-000007 Filed 2026-11-13 Dispute this row
Nuveen, LLC Partly reported under another manager35,423 SH188,451 dollarsHigher by 90 Prior quarter: 35,333Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
RHUMBLINE ADVISERS 32,975 SH175,420 dollarsHigher by 8,633 Prior quarter: 24,342Open filing 0001115418-26-000015 Filed 2026-11-10 Dispute this row
DEUTSCHE BANK AG\ Partly reported under another manager22,495 SH119,673 dollarsLower by 3,343 Prior quarter: 25,838Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row
PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager22,022 SH118 dollarsUnchanged Prior quarter: 22,022Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • LANDSCAPE CAPITAL MANAGEMENT, L.L.C. 167,446 SH
  • Sixth Street Partners Management Company, L.P. 64,220 SH
  • TWO SIGMA INVESTMENTS, LP 15,913 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Commodore Capital LP Common Stock, par value $0.00001 per share9.93,879,705.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001831942-26-000048 Dispute this row
Commodore Capital Master LP Common Stock, par value $0.00001 per share9.93,879,705.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001831942-26-000048 Dispute this row
Robert Egen Atkinson Common Stock, par value $0.00001 per share9.93,879,705.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001831942-26-000048 Dispute this row
Michael Kramarz Common Stock, par value $0.00001 per share9.93,879,705.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001831942-26-000048 Dispute this row
Eric Easom Common Stock, par value $0.00001 per share6.22,409,48609/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-461157 Dispute this row
Coastlands Capital LP Common Stock, par value $0.00001 per share9.993,803,851.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127408 Dispute this row
Coastlands Capital Partners LP Common Stock, par value $0.00001 per share9.993,803,851.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127408 Dispute this row
Coastlands Capital GP LLC Common Stock, par value $0.00001 per share9.993,803,851.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127408 Dispute this row
Coastlands Capital LLC Common Stock, par value $0.00001 per share9.993,803,851.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127408 Dispute this row
Matthew D. Perry Common Stock, par value $0.00001 per share9.993,803,851.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127408 Dispute this row
Almitas Capital LLC Common Stock4.11,479,129.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0002073679-26-000066 Dispute this row
Vivo Opportunity Fund Holdings, L.P. Common Stock, par value $0.00001 per share8.02,864,346.0003/10/2026 Filed 2026-03-13SCHEDULE 13GOpen filing 0001213900-26-027660 Dispute this row
Vivo Opportunity, LLC Common Stock, par value $0.00001 per share8.02,864,346.0003/10/2026 Filed 2026-03-13SCHEDULE 13GOpen filing 0001213900-26-027660 Dispute this row
Vivo Opportunity Cayman Fund, L.P. Common Stock, par value $0.00001 per share0.8289,294.0003/10/2026 Filed 2026-03-13SCHEDULE 13GOpen filing 0001213900-26-027660 Dispute this row
Vivo Opportunity Cayman, LLC Common Stock, par value $0.00001 per share0.8289,294.0003/10/2026 Filed 2026-03-13SCHEDULE 13GOpen filing 0001213900-26-027660 Dispute this row
Commodore Capital LP Common Stock, par value $0.00001 per share9.93,697,435.0003/09/2026 Filed 2026-03-16SCHEDULE 13GOpen filing 0001831942-26-000014 Dispute this row
Commodore Capital Master LP Common Stock, par value $0.00001 per share9.93,697,435.0003/09/2026 Filed 2026-03-16SCHEDULE 13GOpen filing 0001831942-26-000014 Dispute this row
Robert Egen Atkinson Common Stock, par value $0.00001 per share9.93,697,435.0003/09/2026 Filed 2026-03-16SCHEDULE 13GOpen filing 0001831942-26-000014 Dispute this row
Michael Kramarz Common Stock, par value $0.00001 per share9.93,697,435.0003/09/2026 Filed 2026-03-16SCHEDULE 13GOpen filing 0001831942-26-000014 Dispute this row
Integrated Core Strategies (US) LLC Common Stock, par value $0.00001 per share6.02,135,044.0003/06/2026 Filed 2026-03-13SCHEDULE 13GOpen filing 0001104659-26-027730 Dispute this row
Millennium Management LLC Common Stock, par value $0.00001 per share6.32,237,102.0003/06/2026 Filed 2026-03-13SCHEDULE 13GOpen filing 0001104659-26-027730 Dispute this row
Millennium Group Management LLC Common Stock, par value $0.00001 per share6.32,237,102.0003/06/2026 Filed 2026-03-13SCHEDULE 13GOpen filing 0001104659-26-027730 Dispute this row
Israel A. Englander Common Stock, par value $0.00001 per share6.32,237,102.0003/06/2026 Filed 2026-03-13SCHEDULE 13GOpen filing 0001104659-26-027730 Dispute this row
Almitas Capital LLC Common Stock and Warrants5.42,975,164.0012/31/2025 Filed 2026-02-17SCHEDULE 13GOpen filing 0001596468-26-000004 Dispute this row
Eric Easom Common Stock, par value $0.00001 per share7.92,232,00412/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-051535 Dispute this row
Almitas Capital LLC Common Stock and Warrants5.21,428,323.0009/30/2025 Filed 2025-11-14SCHEDULE 13GOpen filing 0001596468-25-000022 Dispute this row
BML Investment Partners, L.P. Common Stock, par value $0.00001 per share1.4427,43206/17/2025 Filed 2025-06-18SCHEDULE 13D/AAmendment 2Open filing 0001373604-25-000092 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,728,591 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015144,973
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to AN2 Therapeutics, Inc.